Christopher Viehbacher, former Sanofi CEO and current managing partner at Gurnet Capital, will be charged with returning Biogen to growth with a second big Alzheimer’s launch looming.

Janssen and Krystal Biotech will soon learn whether the European Medicines Agency considers their respective products to be of potential major public health interest, particularly from the point of view of therapeutic innovation.

The largest show for multinational pharma firms in China shows new approaches to localization may be needed as the country navigates choppy waters.

Verona Pharma’s Phase III ensifentrine, if approved, would be the first new dual-mechanism treatment class for COPD patients in decades. It could propel the UK-based biotech toward profitability, or into the arms of a larger partner.